Entrada Therapeutics (NASDAQ:TRDA) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Entrada Therapeutics (NASDAQ:TRDA - Free Report) in a research report sent to investors on Monday morning,Benzinga reports. They currently have a $20.00 price objective on the stock.

TRDA has been the subject of a number of other research reports. Roth Mkm began coverage on shares of Entrada Therapeutics in a research note on Thursday, December 5th. They set a "buy" rating and a $29.00 target price for the company. Roth Capital raised shares of Entrada Therapeutics to a "strong-buy" rating in a research report on Thursday, December 5th.

Entrada Therapeutics Trading Up 0.5 %

NASDAQ:TRDA traded up $0.04 during trading hours on Monday, hitting $8.80. The stock had a trading volume of 167,060 shares, compared to its average volume of 118,174. The company has a market cap of $330.84 million, a PE ratio of 5.53 and a beta of -0.14. Entrada Therapeutics has a 1-year low of $8.63 and a 1-year high of $21.79. The business has a 50 day simple moving average of $11.83 and a two-hundred day simple moving average of $15.34.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.66) by $0.69. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The business had revenue of $12.25 million for the quarter, compared to analysts' expectations of $11.95 million. Research analysts expect that Entrada Therapeutics will post 1.12 EPS for the current fiscal year.

Remove Ads

Hedge Funds Weigh In On Entrada Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Public Employees Retirement System of Ohio grew its holdings in Entrada Therapeutics by 6.2% in the 4th quarter. Public Employees Retirement System of Ohio now owns 17,259 shares of the company's stock valued at $298,000 after buying an additional 1,000 shares in the last quarter. ExodusPoint Capital Management LP grew its position in shares of Entrada Therapeutics by 7.3% during the fourth quarter. ExodusPoint Capital Management LP now owns 16,453 shares of the company's stock worth $284,000 after acquiring an additional 1,113 shares during the last quarter. WCG Wealth Advisors LLC increased its holdings in shares of Entrada Therapeutics by 6.2% in the fourth quarter. WCG Wealth Advisors LLC now owns 24,030 shares of the company's stock valued at $415,000 after purchasing an additional 1,406 shares during the period. Bank of America Corp DE boosted its holdings in Entrada Therapeutics by 4.9% in the 4th quarter. Bank of America Corp DE now owns 35,721 shares of the company's stock valued at $618,000 after purchasing an additional 1,660 shares in the last quarter. Finally, MetLife Investment Management LLC increased its holdings in shares of Entrada Therapeutics by 11.9% in the 4th quarter. MetLife Investment Management LLC now owns 16,329 shares of the company's stock valued at $282,000 after purchasing an additional 1,731 shares in the last quarter. Institutional investors and hedge funds own 86.39% of the company's stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.